ACYCLOVIR TABLET

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

ACYCLOVIR

Tilgængelig fra:

SANIS HEALTH INC

ATC-kode:

J05AB01

INN (International Name):

ACYCLOVIR

Dosering:

200MG

Lægemiddelform:

TABLET

Sammensætning:

ACYCLOVIR 200MG

Indgivelsesvej:

ORAL

Enheder i pakken:

100/250

Recept type:

Prescription

Terapeutisk område:

NUCLEOSIDES AND NUCLEOTIDES

Produkt oversigt:

Active ingredient group (AIG) number: 0115506002; AHFS:

Autorisation status:

CANCELLED POST MARKET

Autorisation dato:

2014-08-01

Produktets egenskaber

_ _
_Product Monograph – Acyclovir _
_Page 1 _
PRODUCT MONOGRAPH
PR
ACYCLOVIR
Acyclovir, USP
200, 400 and 800 mg Tablets
Manufacturer Standard
ANTIVIRAL AGENT
Sanis Health Inc.
333 Champlain Street, Suite 102
Dieppe, New Brunswick
EIA IP2
Control#: 143847
DATE OF REVISION:
January 18, 2011
_ _
_Product Monograph – Acyclovir _
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE
REACTIONS...................................................................................................
6
DRUG INTERACTIONS
...................................................................................................
9
DOSAGE AND
ADMINISTRATION.............................................................................
10
OVERDOSAGE
...............................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 12
STORAGE AND
STABILITY.........................................................................................
14
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 14
AVAILABILITY OF DOSAGE FORMS
........................................................................
14
PART II: SCIENTIFIC INFORMATION
...............................................................................
15
PHARMACEUTICAL
INFORMATION.........................................................................
15
CLINICAL
TRIALS...............................................